Anti-OKT3 response following prophylactic treatment in paediatric kidney transplant recipients
- PMID: 8518095
- DOI: 10.1007/BF00853215
Anti-OKT3 response following prophylactic treatment in paediatric kidney transplant recipients
Abstract
The anti-OKT3 response was studied in 40 paediatric kidney transplant recipients receiving OTK3 as a prophylactic treatment in association with azathioprine and prednisone. Only 1 patient experienced a reversible acute rejection episode while receiving OKT3. OKT3 induced a rapid disappearance of CD3+ cells, but significant proportions of CD3+ cells reappeared before the end of the treatment in 14 patients. Wide variations in circulating OKT3 levels were observed and in only 50% of patients could stable circulating OKT3 levels be detected until discontinuation of treatment. Anti-OKT3 antibodies detected by the enzyme-linked immunosorbent assay (ELISA) (anti-idiotypic and anti-isotypic antibodies) developed in 91% of patients. Anti-idiotypic antibodies detected by the immunofluorescence inhibition test were found in the sera of 71% of patients, always when high titres of anti-OKT3 antibodies were detected by ELISA. As it has recently been shown that anti-idiotypic antibodies are associated with failure of subsequent OKT3 treatment, we conclude that OKT3 should be restricted to steroid-resistant rejection crises in paediatric patients.
Similar articles
-
OKT3 induction in pediatric renal transplantation.Pediatr Nephrol. 1993 Feb;7(1):45-9. doi: 10.1007/BF00861565. Pediatr Nephrol. 1993. PMID: 8382505
-
Consequences of anti-OKT3 antibody development: OKT3 reuse and long-term graft survival.Transplant Proc. 1993 Apr;25(2 Suppl 1):81-2. Transplant Proc. 1993. PMID: 8465434 No abstract available.
-
Prediction of successful allograft rejection retreatment with OKT3.Transplantation. 1992 Jan;53(1):87-90. doi: 10.1097/00007890-199201000-00016. Transplantation. 1992. PMID: 1733090 Clinical Trial.
-
Antibody response to OKT3 and methods for monitoring.Transplant Proc. 1993 Apr;25(2 Suppl 1):77-80. Transplant Proc. 1993. PMID: 8465433 Review.
-
Immunologic monitoring during OKT3 therapy.Clin Transplant. 1993 Aug;7(4 Pt 2):422-30. Clin Transplant. 1993. PMID: 10146352 Review.
Cited by
-
Immunogenicity of Protein Therapeutics: A Lymph Node Perspective.Front Immunol. 2020 May 14;11:791. doi: 10.3389/fimmu.2020.00791. eCollection 2020. Front Immunol. 2020. PMID: 32477334 Free PMC article. Review.
-
Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection.Drugs. 1996 May;51(5):865-94. doi: 10.2165/00003495-199651050-00010. Drugs. 1996. PMID: 8861551 Review.
References
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials